Prosecution Insights
Last updated: April 19, 2026

Examiner: JOHNSON, TIRONE DEREK

Tech Center 1600 • Art Units: 1600 1675

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
9
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

6.3%
§101 Eligibility
12.5%
§102 Novelty
43.8%
§103 Obviousness
37.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18331475 CANINE CANCER VACCINE Non-Final OA Arizona Board of Regents on behalf of Arizona State University
18276871 METHODS OF TREATING HYPOGONADOTROPIC HYPOGONADISM AND COGNITION IMPAIRMENT FOLLOWING A TRAUMATIC BRAIN INJURY Non-Final OA UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
18283385 MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING Non-Final OA INNATE PHARMA
18201626 USE OF ANTI-IL-27 ANTIBODIES Non-Final OA F. HOFFMANN-LA ROCHE AG
18035837 COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE Non-Final OA PALENA THERAPEUTICS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month